Moleculin Biotech, Inc.

Healthcare · Biotechnology · United States

Last price 8.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 8.49M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ...